구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | ladiratuzumab vedotin |
Overview Company | Seagen Inc. |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | SDP-LIV1, a Novel and Optimized LIV-1 Antibody-Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors.. LIV-1 is a transmembrane protein belonging to the zinc transporter family and represents a promising target for antibody-drug conjugate (ADC) therapy because of its broad expression in tumors and limited normal tissue expression.… |
Clinical Safety signal | SDP-LIV1, a Novel and Optimized LIV-1 Antibody-Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors.. LIV-1 is a transmembrane protein belonging to the zinc transporter family and represents a promising target for antibody-drug conjugate (ADC) therapy because of its broad expression in tumors and limited normal tissue expression.… |
Clinical Selected reported efficacy | ORR 34% |
Clinical Reported ORR | 34% |
Clinical Result source | ClinicalTrials.gov NCT03310957 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03310957 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | ladiratuzumab vedotin |
Overview Company | Seagen Inc. |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | SDP-LIV1, a Novel and Optimized LIV-1 Antibody-Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors.. LIV-1 is a transmembrane protein belonging to the zinc transporter family and represents a promising target for antibody-drug conjugate (ADC) therapy because of its broad expression in tumors and limited normal tissue expression.… |
Clinical Safety signal | SDP-LIV1, a Novel and Optimized LIV-1 Antibody-Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors.. LIV-1 is a transmembrane protein belonging to the zinc transporter family and represents a promising target for antibody-drug conjugate (ADC) therapy because of its broad expression in tumors and limited normal tissue expression.… |
Clinical Selected reported efficacy | ORR 34% |
Clinical Reported ORR | 34% |
Clinical Result source | ClinicalTrials.gov NCT03310957 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03310957 |
추천 비교
추천 비교